<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00081783</url>
  </required_header>
  <id_info>
    <org_study_id>XT009</org_study_id>
    <nct_id>NCT00081783</nct_id>
  </id_info>
  <brief_title>Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients</brief_title>
  <official_title>A Phase II Study of Xcellerated T CellsTM in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma (NHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xcyte Therapies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xcyte Therapies</source>
  <brief_summary>
    <textblock>
      This is a Phase II single arm study of a novel T cell immunotherapy in patients with indolent&#xD;
      non-Hodgkin's lymphoma (NHL). Eligible patients will have relapsed or refractory disease&#xD;
      after receiving at least one and no more than four prior regimens. Patients will receive&#xD;
      Xcellerated T CellsTM, an ex vivo activated and expanded autologous T cell product, in an&#xD;
      attempt to enhance immune responses with anti-tumor activity. The primary endpoint of the&#xD;
      study is to evaluate the efficacy of Xcellerated T Cells in patients with indolent NHL.&#xD;
      Secondary endpoints are to evaluate the safety of the therapy in this patient population, and&#xD;
      to evaluate changes in the number and phenotype of T- and B-lymphocytes, as well as changes&#xD;
      in the T cell receptor repertoire, hemoglobin levels, platelet counts and quantitative&#xD;
      immunoglobulin levels. In a subset of patients, fine-needle aspirates of malignant lymph&#xD;
      nodes will be performed to assess changes in the lymphocyte composition and phenotype. Bone&#xD;
      marrow aspirates will be similarly evaluated. Finally, anti-tumor immune responses will be&#xD;
      evaluated in patients amenable to biopsy of enlarged lymph nodes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2004</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>40</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xcellerated T Cells</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Indolent non-Hodgkin's Lymphoma (NHL), with one of the following subtypes according to&#xD;
             the REAL Classification: follicular lymphoma, small lymphocytic lymphoma (SLL),&#xD;
             extranodal marginal zone B-cell lymphoma (MALT), nodal marginal zone B-cell lymphoma&#xD;
             (monocytoid B-cell lymphoma), splenic marginal zone lymphoma (splenic lymphoma with&#xD;
             villous lymphocytes) and mantle cell lymphoma. Other subtypes require approval of the&#xD;
             Medical Monitor. At least 16 patients with small lymphocytic lymphoma, and no more&#xD;
             than eight patients with mantle cell lymphoma will be enrolled.&#xD;
&#xD;
          -  Stage III or IV disease at any time in the past&#xD;
&#xD;
          -  Relapsed or refractory disease following most recent treatment. Patients are&#xD;
             considered to have refractory disease if their last treatment course did not result in&#xD;
             a complete or partial response, or if time to disease progression was six months or&#xD;
             less. Patients are considered to have relapsed disease if time to disease progression&#xD;
             is more than six months. Patients who have achieved a partial or complete response&#xD;
             following most recent therapy must have demonstrated progressive disease.&#xD;
&#xD;
          -  Patients must have received at least one prior course of systemic therapy for NHL and&#xD;
             no more than four prior courses of therapy. Repeat courses of the same therapeutic&#xD;
             regimen separated in time by six or more months are considered separate treatment&#xD;
             courses, with the exception of single-agent rituximab. Patients with more than four&#xD;
             prior courses of therapy may be enrolled at the discretion of the Medical Monitor&#xD;
             after discussion with the Investigator.&#xD;
&#xD;
          -  Radiographically bi-dimensionally measurable disease. Imaging need not be performed&#xD;
             within 15 days prior to registration. Prior scans are acceptable provided that there&#xD;
             has been no intervening therapy for NHL. Scans will be obtained at baseline, following&#xD;
             registration.&#xD;
&#xD;
          -  Age of at least 18 years&#xD;
&#xD;
          -  ECOG performance status of 0 to 2&#xD;
&#xD;
          -  White blood count (WBC) ≥ 3,000/mm3, absolute neutrophil count (ANC) ≥ 1000/mm3&#xD;
&#xD;
          -  CD3+ &gt; 1% of total peripheral white blood cell count by flow cytometry&#xD;
&#xD;
          -  Platelet count &gt; 50,000/mm3&#xD;
&#xD;
          -  Hemoglobin ³ 10.0 g/dL. Transfusion with red blood cells or use of erythropoietin is&#xD;
             permissible.&#xD;
&#xD;
          -  Serum total bilirubin and alanine aminotransferase (ALT) ≤ 2.0 times the upper limit&#xD;
             of normal&#xD;
&#xD;
          -  Serum creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Serum human anti-mouse antibody (HAMA) titer undetectable or within the normal range,&#xD;
             and no history of symptomatic allergic reactions to mice or murine (mouse) proteins.&#xD;
             Patients with elevated HAMA levels may be enrolled at the discretion of the Medical&#xD;
             Monitor after discussion with the Investigator.&#xD;
&#xD;
          -  Negative test results for current/active infection with HIV-1, HIV-2, HTLV-1, HTLV-2,&#xD;
             hepatitis B and hepatitis C within 30 days of registration. (Antibody, antigen and&#xD;
             nucleic acid tests acceptable, depending on institutional standards)&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test. Both men&#xD;
             and women agree to use a medically accepted form of contraception from the time of&#xD;
             initial screening through completion of the study.&#xD;
&#xD;
          -  Able to comprehend and provide signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of Hodgkin's lymphoma, Burkitt's lymphoma, diffuse large B-cell lymphoma,&#xD;
             primary mediastinal B-cell lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia,&#xD;
             primary central nervous system lymphoma or any other aggressive lymphoma&#xD;
&#xD;
          -  Any T cell lymphoma&#xD;
&#xD;
          -  Evidence of primary cutaneous anaplastic large cell lymphoma, Richter's Syndrome,&#xD;
             large granular lymphocytosis and Sézary-cell leukemia. Patients with a prior diagnosis&#xD;
             of chronic lymphocytic leukemia, as evidenced by absolute peripheral lymphocyte count&#xD;
             of greater than 5,000 per mm3 at any time in the past, are not eligible.&#xD;
&#xD;
          -  Leukemic manifestations of non-Hodgkin's lymphoma. Small lymphocytic lymphoma patients&#xD;
             with peripheral lymphocyte count greater than 5,000 per mm3&#xD;
&#xD;
          -  Receipt of any chemotherapy, monoclonal antibody, investigational or other systemic&#xD;
             therapy (except glucocorticoids as noted below) for the treatment of NHL within 2&#xD;
             months prior to registration&#xD;
&#xD;
          -  Receipt of glucocorticoids (with the exception of inhaled glucocorticoids) within 1&#xD;
             month prior to registration&#xD;
&#xD;
          -  Receipt of intravenous immunoglobulin (IVIG) within 1 month of registration&#xD;
&#xD;
          -  Registration for, or plans to participate in, any other clinical trial of an&#xD;
             investigational agent concurrently with this trial&#xD;
&#xD;
          -  History of malignancy other than NHL within five years of registration, except&#xD;
             adequately treated basal or squamous cell skin cancer or in situ carcinoma of the&#xD;
             cervix. Other exceptions must be approved by the Xcyte Therapies' Medical Monitor&#xD;
             prior to registration.&#xD;
&#xD;
          -  Infection requiring treatment with antibiotics, antifungal, or antiviral agents within&#xD;
             seven days of registration&#xD;
&#xD;
          -  Active autoimmune disease requiring systemic treatment&#xD;
&#xD;
          -  Major organ system dysfunction including (but not limited to): New York Heart&#xD;
             Association Class III or IV, severe pulmonary, renal, hepatic, gastrointestinal,&#xD;
             neurologic or psychiatric dysfunction which would impair patient's ability to&#xD;
             participate in the trial&#xD;
&#xD;
          -  Any other pertinent medical or psychological condition which leads the Investigator to&#xD;
             believe the study would not be appropriate treatment or in the patient's best interest&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark W. Frohlich, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Xcyte Therapies</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vicki M. Mizuno</last_name>
    <phone>206-262-6251</phone>
    <email>vmizuno@xcytetherapies.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>California Cancer Care</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Chang</last_name>
      <phone>415-925-5040</phone>
      <email>JChang@cal-cancer-care.com</email>
    </contact>
    <investigator>
      <last_name>Jennifer B. Lucas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lynne Smith</last_name>
      <phone>323-865-0371</phone>
      <email>diansmi@usc.edu</email>
    </contact>
    <investigator>
      <last_name>Ann Mohrbacher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vineeta Prasad</last_name>
      <phone>858-822-0337</phone>
      <email>vprasad@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Januario E. Castro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sharp Memorial Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Wood</last_name>
      <phone>858-939-5062</phone>
      <email>cathy.wood@sharp.com</email>
    </contact>
    <investigator>
      <last_name>Charles Redfern, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Zhang</last_name>
      <phone>415-476-3741</phone>
      <email>jzhang@medicine.ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Lawrence D. Kaplan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juli Murphy, BS, CCRC</last_name>
      <phone>303-285-5087</phone>
      <email>juli.murphy@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Peter McSweeney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Cancer Care</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Andrews</last_name>
      <phone>404-851-2359</phone>
      <email>kandrews@atlantacancercare.com</email>
    </contact>
    <investigator>
      <last_name>Ronald G. Steis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Newton, RN</last_name>
      <phone>410-502-7985</phone>
      <email>meusesu@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Ian W. Flinn, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Cancer &amp; Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Bongiorno, RN, BSN</last_name>
      <phone>301-571-0019</phone>
      <email>nbongiorno@ccbdmd.com</email>
    </contact>
    <investigator>
      <last_name>Ralph V. Boccia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Boyajian</last_name>
      <phone>617-632-3352</phone>
      <phone_ext>42314</phone_ext>
      <email>Richard_Boyajian@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Arnold Freedman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Bryan</last_name>
      <phone>314-362-6359</phone>
      <email>kbryan@im.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Nancy L. Bartlett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Martin</last_name>
      <phone>732-235-8995</phone>
      <email>martinj4@umdnj.edu</email>
    </contact>
    <investigator>
      <last_name>Roger K. Strair, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Weiss</last_name>
      <phone>614-293-3437</phone>
      <email>Weiss-3@medctr.osu.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aubyn Grant, CCRP</last_name>
      <phone>503-494-5074</phone>
      <email>granta@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Brandon Hayes-Lattin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of the Carolinas</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Williams, RN</last_name>
      <phone>864-241-6251</phone>
      <email>kimberly.williams@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Joe J. Stephenson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Ayala</last_name>
      <phone>713-792-3610</phone>
      <email>abayala@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Peter W. McLaughlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toni Oien, CCRC</last_name>
      <phone>206-386-2831</phone>
      <email>toni.oien@swedish.org</email>
    </contact>
    <investigator>
      <last_name>Michael S. Milder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Mason</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Perrault-Gray</last_name>
      <phone>206-583-6559</phone>
      <phone_ext>61870</phone_ext>
      <email>Aimee.PerraultGray@vmmc.org</email>
    </contact>
    <investigator>
      <last_name>David M. Aboulafia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2005</verification_date>
  <study_first_submitted>April 20, 2004</study_first_submitted>
  <study_first_submitted_qc>April 21, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2004</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>T Cells</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>NHL</keyword>
  <keyword>Xcellerated T Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

